IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 (“Fiscal 2024”).
IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 (“Fiscal 2024”).